Results 91 to 100 of about 67,507 (290)

Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment [PDF]

Prostate Cancer, 2012
Patients with castration-resistant prostate cancer (CRPC), who progress after docetaxel therapy, had until very recently, only a few therapeutic options. Recent advances in this field brought about new perspectives in the treatment of this disease. Molecular, basic, and translational research has given us a better understanding on the mechanisms of ...
Amaral, Teresa, Macedo, Daniela, Fernandes, Isabel, Costa, Luis   +3 more
openaire   +5 more sources

PVT1 lincRNA signals an androgen‐dependent transcriptional activation program of oncogenes in prostate cancer cells

International Journal of Cancer, EarlyView.
What's New? Unraveling the networks that regulate androgen receptor (AR) function is critical to better understanding prostate cancer development and progression. Of particular interest in this regard is the long non‐coding RNA PVT1, which regulates gene expression in cancer and is upregulated in prostate tumors.
Maria Gabriela Berzoti‐Coelho, Fabio Nunes de Mello, Ana Carolina Tahira, Gabriel Nakanishi Fortes, Agatha Fischer‐Carvalho, Pedro Jardim Poli, Murilo Sena Amaral, Sergio Verjovski‐Almeida   +7 more
wiley   +1 more source

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer

IJU Case Reports, 2019
Introduction Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. Case presentation A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started ...
Yoshinori Yanai, Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya   +3 more
doaj   +1 more source

Systemic treatment for metastatic prostate cancer

Asian Journal of Urology, 2019
The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy ...
Gwenaelle Gravis
doaj   +1 more source

Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. [PDF]

, 2017
Suppression of androgen receptor (AR) activity in prostate cancer by androgen depletion or direct AR antagonist treatment, although initially effective, leads to incurable castration-resistant prostate cancer (CRPC) via compensatory mechanisms including ...
Anderson, Kelsey N., Chen, Nan, Kania, Blase, Kim, Felix J., Knudsen, Karen E., Longen, Charles G., Maher, Christina M., Ostrander, William F., Oyer, Halley M., Salvino, Joseph M., Thomas, Jeffrey D.   +10 more
core   +1 more source

Negative regulation of the androgen receptor gene through a primate specific androgen response element present in the 5' UTR [PDF]

, 2014
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Hay, Colin W, Hunter, Irene, Lavery, Derek N, MacKenzie, Alasdair, McEwan, Iain J, Watt, Kate   +5 more
core   +2 more sources

Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. [PDF]

, 2020
BackgroundCTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire.
Cham, Jason, Fong, Grant, Fong, Lawrence, He, Tao, Kwek, Serena, Oh, David Y, Paciorek, Alan, Zhang, Li   +7 more
core   +1 more source

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2019
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.We conducted a randomized, double-blind, placebo-controlled, phase 3 trial ...
Fizazi, Karim, Shore, Neal, Tammela, Teuvo L, Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Kuss, Iris, Kappeler, Christian, Snapir, Amir, Sarapohja, Toni, Smith, Matthew R, for the ARAMIS Investigators, Aglietta, Massimo, Damiano, Rocco, Facchini, Gaetano, Gasparro, Donatello, Mucciardi, Giuseppe, Natoli, Clara, Sabbatini, Roberto, Scagliotti, Giorgio, Schepisi, Giuseppe, Serretta ,Vincenzo   +24 more
openaire   +3 more sources

Organoids and organ‐on‐a‐chip models for investigating the pathophysiology of the human reproductive system

Interdisciplinary Medicine, EarlyView.
Organoids and organ‐on‐a‐chips are advancing reproductive system research. In the female reproductive system, applications include cancer organoid models, placental chips, and hormone simulation models. For the male reproductive system, research focuses on drug resistance mechanisms, co‐culture platforms, and infertility studies. These refined in vitro
Hongqi Zhang, Shiwen Deng, Fangfang Jin, Jiayao Qu, Xiang Fan, Peng Chen, Xinrong Fan   +6 more
wiley   +1 more source

Castration-resistant prostate cancer: systemic therapy in 2012

Clinics, 2012
Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide. It is typically diagnosed in its early stages, and the disease exhibits a relatively indolent course in most patients. Despite the curability of localized disease
Fernando C. Maluf, Oren Smaletz, Daniel Herchenhorn   +2 more
doaj   +1 more source